- Home
- ARWR vs SPRY Comparison
ARWR vs SPRY Comparison
Compare ARWR & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARWR
- SPRY
- Stock Information
- Founded
- ARWR 2003
- SPRY 2015
- Country
- ARWR United States
- SPRY United States
- Employees
- ARWR N/A
- SPRY N/A
- Industry
- ARWR Biotechnology: Pharmaceutical Preparations
- SPRY Biotechnology: Pharmaceutical Preparations
- Sector
- ARWR Health Care
- SPRY Health Care
- Exchange
- ARWR Nasdaq
- SPRY Nasdaq
- Market Cap
- ARWR 1.8B
- SPRY 1.6B
- IPO Year
- ARWR 1993
- SPRY N/A
- Fundamental
- Price
- ARWR $18.31
- SPRY $17.69
- Analyst Decision
- ARWR Buy
- SPRY Strong Buy
- Analyst Count
- ARWR 8
- SPRY 4
- Target Price
- ARWR $43.71
- SPRY $28.75
- AVG Volume (30 Days)
- ARWR 1.6M
- SPRY 1.6M
- Earning Date
- ARWR 08-07-2025
- SPRY 08-05-2025
- Dividend Yield
- ARWR N/A
- SPRY N/A
- EPS Growth
- ARWR N/A
- SPRY N/A
- EPS
- ARWR N/A
- SPRY N/A
- Revenue
- ARWR $545,209,000.00
- SPRY $97,122,000.00
- Revenue This Year
- ARWR $21,924.50
- SPRY N/A
- Revenue Next Year
- ARWR N/A
- SPRY $170.64
- P/E Ratio
- ARWR N/A
- SPRY N/A
- Revenue Growth
- ARWR 1436.97
- SPRY 971120.00
- 52 Week Low
- ARWR $9.57
- SPRY $8.91
- 52 Week High
- ARWR $30.41
- SPRY $18.90
- Technical
- Relative Strength Index (RSI)
- ARWR 66.51
- SPRY 60.97
- Support Level
- ARWR $16.45
- SPRY $16.40
- Resistance Level
- ARWR $19.24
- SPRY $18.05
- Average True Range (ATR)
- ARWR 0.79
- SPRY 1.06
- MACD
- ARWR 0.25
- SPRY 0.03
- Stochastic Oscillator
- ARWR 77.43
- SPRY 62.54
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.